NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has closed a $3.9 million public offering of its common stock.

The previously announced offering included the sale of 1.2 million shares of Interpace common stock at $3 per share, as well as 108,000 additional shares related to the full exercise of an over-allotment option granted to the underwriters of the transaction.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.